Showing 6491-6500 of 7019 results for "".
- TetraLogic Acquires Shape Pharmaceuticals, Inc.https://practicaldermatology.com/news/20140407-tetralogic_acquires_shape_pharmaceuticals_inc/2459275/TetraLogic Pharmaceuticals Corporation has entered an agreement to acquire Shape Pharmaceuticals, a biotechnology company. Shape Pharmaceuticals is developing SHAPE, which is a tissue-targeted HDAC inhibitor in a topical gel formulation to treat stage IA-IIA Cutaneous T-Cell Lymphoma.
- Alma Lasers Hosts Special Programs at the 34th ASLMS Conference in Phoenixhttps://practicaldermatology.com/news/20140403-alma_lasers_hosts_special_programs_at_the_34th_aslms_conference_in_phoenix/2459279/The ASLMS, provider of laser, light-based, radio frequency and ultrasound technologies, invites guests to hear from leading experts. Michael Gold, of Gold Skin Care in Nashville, Tennessee, will moderate the night's discussion. Others include: Macrene Alexiades-Armenakas, MD, director a
- April is Rosacea Awareness Monthhttps://practicaldermatology.com/news/20140401-april_is_rosacea_awareness_month/2459281/April is Rosacea Awareness Month and the National Rosacea Society encourages physicians and patients to raise awareness of the disease and its impact on affected individuals. This red-face disorder affects more than 16 million Americans between the ages of 30 and 60. It covers the spectru
- SGR Patch: AADA Disappointed By Congressional Actionhttps://practicaldermatology.com/news/20140401-sgr_patch_aada_disappointed_by_congressional_action/2459285/Statement from Brett M. Coldiron, MD, FAAD President, American Academy of Dermatology Association: The U.S. House of Representatives and Senate have averted a 24 percent cut in Medicare physician payments by agreeing to a one-year short-term measure (HR 4302) to maintain current Medicare payment r
- ZO Medical Products Launches in the Middle Easthttps://practicaldermatology.com/news/20140331-zo_medical_products_launches_in_the_middle_east/2459288/ZO Skin Health and Cellogique launched ZO products at the Dubai World Dermatology & Laser Conference Exhibition. Dr. Zein Obagi, board certified dermatologist, developed this product with hopes of representing his skin health principles. “These products empowe
- Frost & Sullivan Commends Sensus for the Development of SRT-100™ and SRT-100 Vision™, its Low-energy Radiation Therapy Systems for Treating Skin Cancerhttps://practicaldermatology.com/news/20140331-frost__sullivan_commends_sensus_for_the_development_of_srt-100_and_srt-100_vision_its_low-energy_radiation_therapy_systems_for_treating_skin_cancer/2459289/Based on its recent analysis of the non-melanoma skin cancer therapy market, Frost & Sullivan recognizes Sensus Healthcare LLC with the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. Sensus uses a technique known as superficial radiation therapy (SRT) in its two lo
- Galderma Announces Positive Results of Phase 3 Trials of Investigational Ivermectin 1% Targeting Papulopustular Rosaceahttps://practicaldermatology.com/news/20140325-galderma_announces_positive_results_of_phase_3_trials_of_investigational_ivermectin_1_targeting_papulopustular_rosacea/2459295/Galderma Laboratories, L.P. today announced the results of two pivotal phase 3 trials of ivermectin 1%, an investigational drug being evaluated for the treatment of papulopustular (inflammatory) rosacea. The data were presented at a Late-Breaking session of the 72nd annual meeting of the American Ac
- Practical Dermatology® Magazine Launches Daily Coverage of Denver Annual Meetinghttps://practicaldermatology.com/news/20140324-practical_dermatology_magazine_launches_daily_coverage_of_denver_annual_meeting/2459297/Bryn Mawr Communications III, LLC's Practical Dermatology® magazine and DermTube.com this weekend launched daily video coverage of the Annual Meeting in Denver with host Joel L. Cohen, MD, FAAD. Dr. Cohen,
- Phase 3 Results for Novartis' Secukinumab Reportedhttps://practicaldermatology.com/news/20140322-phase_3_results_for_novartis_secukinumab_reported/2459300/Results from the Phase III FEATURE and JUNCTURE studies show Novartis' secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011)
- SeroVital®–hgh AKA the "Fountain of Youth" Pillhttps://practicaldermatology.com/news/20140320-serovitalhgh_aka_the_fountain_of_youth_pill/2459306/SeroVital®–hgh is a growth hormone that the maker says can reduce wrinkles, tighten skin, decrease body fat and increase energy. Gina Daines, spokesperson for SanMedica International™ said, "Human growth hormone is no longer solely the province of male athletes. Research is revealing tha